T1	Participants 20 123	adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma
T2	Participants 189 291	tumor-infiltrating lymphocytes (TIL) as adjuvant therapy for stage III (regional lymph nodes) melanoma
T3	Participants 341 362	detectable metastases
T4	Participants 547 632	Eighty-eight patients determined as eligible for treatment were enrolled in the study
T5	Participants 1475 1578	efficiency of TIL in stage III melanoma (AJCC) is directly related to the number of invaded lymph nodes
T6	Participants 1764 1820	future vaccine development for the treatment of melanoma
